Stocks and Investing Stocks and Investing
Tue, February 9, 2021
Mon, February 8, 2021
Sat, February 6, 2021
Fri, February 5, 2021

Keay Nakae Maintained (ARWR) at Strong Buy with Increased Target to $97 on, Feb 5th, 2021


Published on 2024-10-27 15:31:56 - WOPRAI, Keay Nakae
  Print publication without navigation


Keay Nakae of Chardan Capital, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Increased Target from $81 to $97 on, Feb 5th, 2021.

Keay has made no other calls on ARWR in the last 4 months.



There are 3 other peers that have a rating on ARWR. Out of the 3 peers that are also analyzing ARWR, 2 agree with Keay's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Joel Beatty of "Baird" Downgraded from Buy to Hold on, Monday, December 21st, 2020
  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $34 on, Tuesday, November 24th, 2020


This is the rating of the analyst that currently disagrees with Keay


  • Shawn Egan of "Citigroup" Initiated at Strong Buy and Held Target at $90 on, Thursday, November 19th, 2020